Ascendis Pharma A/S expected to post a loss of €2.66 a share - Earnings Preview

Ascendis Pharma A/S

26/04/2023 03:03

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
rise in quarterly revenue when it reports  results on April 27. 
    * The Hellerup Denmark-based   company is expected to report
 a
215.2% increase in revenue to €21.525 million from €6.83 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ascendis Pharma A/S
is
for a loss of €2.66 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $142​, above​ its last closing price of $78.36. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -2.44       -2.56      -3.70     Missed  -44.5
 Sep. 30 2022  -2.49       -2.49      -3.03     Missed  -21.7
 Jun. 30 2022  -2.08       -2.13      -1.46     Beat    31.5​
 Mar. 31 2022  -1.98       -2.00      -2.21     Missed  -10.5
 ​​Dec.        -2.39       -2.34      -1.87     Beat    20.2
 31 2021                                                
 Sep. 30 2021  -2.30       -2.29      -1.47     Beat    35.9​
 Jun. 30 2021  -2.22       -2.23      -2.50     Missed  -12.3
 Mar. 31 2021  -1.70       -1.71      -1.17     Beat    31.4
 This summary was machine generated April 26 at 02:03 GMT.  All
figures in euros  unless otherwise stated